Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20705097 | 1.00 | BUB1 (0.40) | BUB1USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL16414303 | 0.93 | BUB1 (0.39) | BUB1USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL31267823 | 0.87 | BUB1 (0.35) | BUB1DDB1CRBNCTSK | |
| SCHEMBL22295948 | 0.85 | BUB1 (0.34) | BUB1GAA | |
| SCHEMBL27228232 | 0.82 | BUB1 (0.42) | BUB1USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL22214360 | 0.82 | BUB1 (0.35) | BUB1USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL20704993 | 0.82 | BUB1 (0.35) | BUB1USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL24248777 | 0.80 | CYP3A4 (0.36) | USP2GAAALDH1A1 | |
| SCHEMBL29431708 | 0.80 | USP2 (0.38) | BUB1USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL20712674 | 0.80 | BUB1 (0.34) | BUB1USP2SMN1; SMN2NR1H2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724441-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | Revir Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024251212-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | REVIR THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024251211-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR MODULATING SPLICING OF MSH3 | REVIR THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240368163-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024182747-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-4396177-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023034827-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11326165-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11091475-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-11021708-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008572-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200224199-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11326165-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | BUB1 3104/4885USP2 2509/4885SMN1; SMN2 123/4885 |
| US-20240368163-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | BUB1 3228/4885USP2 3075/4885SMN1; SMN2 301/4885 |
| US-11021708-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | BUB1 3104/4885USP2 2509/4885SMN1; SMN2 123/4885 |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | BUB1 3104/4885USP2 2509/4885SMN1; SMN2 123/4885 |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | BUB1 3486/4885USP2 2657/4885SMN1; SMN2 124/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | BUB1 3104/4885USP2 2509/4885SMN1; SMN2 123/4885 |
| US-11008572-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | BUB1 3104/4885USP2 2509/4885SMN1; SMN2 123/4885 |
| US-11091475-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | BUB1 3104/4885USP2 2509/4885SMN1; SMN2 123/4885 |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | BUB1 3486/4885USP2 2657/4885SMN1; SMN2 124/4885 |
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | BUB1 3104/4885USP2 2509/4885SMN1; SMN2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.